Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 12, 2004, Pages 1601-1606

  Breyer Pfaff, U ^a   Nill, K ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE KETONE REDUCTASE; ALDOKETOREDUCTASE 1C1; ALDOKETOREDUCTASE 1C2; ALDOKETOREDUCTASE 1C4; CARBONYL DERIVATIVE; CARBONYL REDUCTASE; DOLASETRON MESILATE; ISOENZYME; NALTREXOL; NALTREXONE; OPIATE ANTAGONIST; OXIDOREDUCTASE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG METABOLISM; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIVER CYTOSOL; REACTION ANALYSIS; REDUCTION;

ALCOHOL OXIDOREDUCTASES; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; LIVER; NALTREXONE; OXIDATION-REDUCTION; OXIDOREDUCTASES; QUINOLIZINES;

EID: 10044298325     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357045020     Document Type: Article

References (32)

1. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells, Eur. J. Pharmacol. 219: 9-13
2. Boxenbaum, H., Gillespie, T., Heck, K., Hahne, W. (1992) Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm. Drug Dispos. 13: 693-701
3. Boxenbaum, H., Gillespie, T., Heck, K., Hahne, W. (1993) Human dolasetron pharmacokinetics: II. Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm. Drug Dispos. 14: 131-141
4. Breyer-Pfaff, U., Nill, K. (2000) High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver. Biochem. Pharmacol. 59: 249-260
5. Chiarotto, J. A., Wainer, I. W. (1995) Determination of metyrapone and the enantiomers of its chiral metabolite metyrapol in human plasma and urine using coupled achiral-chiral liquid chromatography. J. Chromatogr. B 665: 147-154
6. Dayton, H. E., Inturrisi, C. E. (1976) The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat. Drug Metab. Dispos. 4: 474-478
7. Dow, J., Berg, C. (1995) Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs, and humans. Chirality 7: 342-348
8. Felsted, R. L., Bachur, N. R. (1980) Mammalian carbonyl reductases. Drug Metab. Rev. 11: 1-60
9. Ferrari, A., Bertolotti, M., Dell'Utri, A., Avico, U., Sternieri, E. (1998) Serum time course of naltrexone and 6β-naltrexol levels during long term treatment in drug addicts. Drug Alcohol Depend. 52: 211-220
10. Galettis, P., Boutagy, J., Ma, D. D. F. (1994) Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br. J. Cancer 70: 324-329
11. Gonzalez, J. P., Brogden, R. N. (1988) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35: 192-213
12. Jörnvall, H., Persson, B., Krook, M., Atrian, S., Gonzàlez-Duarte, R., Jeffery, J., Ghosh, D (1995) Short-chain dehydrogenases/reductases (SDR). Biochemistry 34: 6003-6013
13. Kudo, S., Ishizaki, T. (1999) Pharmacokinetics of haloperidol. An update. Clin. Pharmacokinet. 37: 435-456
14. Kume, T., Iwasa, H., Shiraishi, H., Yokoi, T., Nagashima, K., Otsuka, M., Terada, T., Takagi, T., Hara, A., Kamataki, T. (1999) Characterization of a novel variant (S145C/L311V) of 3α-hydroxysteroid/dihydrodiol dehydrogenase in human liver. Pharmacogenetics 9: 763-771
15. Lam, Y. W., Jann, M. W., Chand, W. H., Yu, H. S., Lin, S. K., Chen, H., Davis, C. M. (1995) Intra- and interethnic variability in reduced haloperidol to haloperidol ratios. J. Clin. Pharmacol. 35: 128-136
16. McCaul, M. E., Wand, G. S., Rohde, C., Lee, S. M. (2000) Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol. Clin. Exp. Res. 24: 1385-1391
17. Meyer, M. C., Straughn, A. B., Lo, M. W., Schary, W. L., Whitney, C. C. (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiatry 45 (9 Pt. 2): 15-19
18. O'Connor, T., Ireland, L. S., Harrison, D. J., Hayes, J. D. (1999) Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem. J. 343: 487-504
19. Ohara, H., Miyabe, Y., Deyashiki, Y., Matsuura, K., Hara, A. (1995) Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol. 50: 221-227
20. Oppermann, U., Filling, C., Hult, M., Shafqat, N., Wu, X., Lindh, M., Shafqat, J., Nordling, E., Kallberg, Y., Persson, B., Jörnvall, H. (2003) Short-chain dehydrogenases/reductases (SDR): the 2002 update. Chem.-Biol. Interact. 143-144: 247-253
21. Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C. F., Lin, H. K., Ma, H., Moore, M., Palackal, N., Ratnam, K. (2000) Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351: 67-77
22. Penning, T. M., Jin, Y., Steckelbroeck, S., Lanišnik Rizner, T., Lewis, M. (2004) Structure-function of human 3α-hydroxysteroid dehydrogenases: genes and proteins. Mol. Cell. Endocrinol. 215: 63-72
23. 3 receptor antagonists in antineoplastic therapy-induced emesis. Drug Saf. 18: 43-56
24. Porter, S. J., Somogyi, A. A., White, J. M. (2000) Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. Br. J. Clin. Pharmacol. 50: 465-471
25. Porter, S. J., Somogyi, A. A., White, J. M. (2002) In vivo and in vitro potency studies of 6β-naltrexol, the major human metabolite of naltrexone. Addic. Biol. 7: 219-225
26. Roila, F., Del Favero, A. (1995) Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. 29: 95-109
27. Rukstalis, M. R., Stromberg, M. F., O'Brien, C. P., Volpicelli, J. R. (2000) 6-β-Naltrexol reduces alcohol consumption in rats. Alcohol. Clin. Exp. Res. 24: 1593-1596
28. Stubbs, K., Martin, L. A., Dimmitt, D. C., Pready, N., Hahne, W. F. (1997) Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron me;sylate in healthy volunteers and patients with hepatic dysfunction. J. Clin. Pharmacol. 37: 926-936
29. Verebey, K., Volavka, J., Mule, S. J., Resnick, R. B. (1976) Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacoil. Ther. 20: 315-328
30. Wall, M. E., Brine, D. R., Perez-Reyss, M. (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab. Dispos. 9: 369-375
31. Wermuth, B. (1981) Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J. Biol. Chem. 256: 1206-1213
32. Wirth, H., Wermuth, B. (1992) Immunohistochemical localization of carbonyl reductase in human tissues. J. Histochem. Cytochem. 40: 1857-1863